Comparative CNS Pharmacology of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Comparative CNS Pharmacology of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis ; volume:24 ; number:2 ; day:5 ; month:7 ; year:2024 ; pages:263-274 ; date:6.2024
Drugs in R & D ; 24, Heft 2 (5.7.2024), 263-274, 6.2024
- Urheber
-
Turner, Timothy J.
Brun, Pricilla
Gruber, Ross C.
Ofengeim, Dimitry
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-024-00468-4
- URN
-
urn:nbn:de:101:1-2410291026221.251676999371
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Turner, Timothy J.
- Brun, Pricilla
- Gruber, Ross C.
- Ofengeim, Dimitry
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Integrin signaling shaping BTK-inhibitor resistance
Responses to the selective bruton's tyrosine kinase (btk) inhibitor tirabrutinib (ono/gs-4059) in diffuse large b-cell lymphoma cell lines
Second-generation inhibitors of Bruton tyrosine kinase
Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
BTK
BTK
BTK
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Integrin signaling shaping BTK-inhibitor resistance
Responses to the selective bruton's tyrosine kinase (btk) inhibitor tirabrutinib (ono/gs-4059) in diffuse large b-cell lymphoma cell lines
Second-generation inhibitors of Bruton tyrosine kinase
Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
BTK
BTK
BTK
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Integrin signaling shaping BTK-inhibitor resistance
Responses to the selective bruton's tyrosine kinase (btk) inhibitor tirabrutinib (ono/gs-4059) in diffuse large b-cell lymphoma cell lines
Second-generation inhibitors of Bruton tyrosine kinase
Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
BTK
BTK